A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles

Kangfu Chen, Bill T.V. Duong, Sharif U. Ahmed, Piriththiv Dhavarasa, Z Wang, Mahmoud Labib, Connor Flynn, Jingya Xu, Yi Y. Zhang, H Wang, Xiaolong Yang, Jagotamoy Das, Hossein Zargartalebi, Yuan Ma, Shana O. Kelley*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Downloads (Pure)

Abstract

Exosomal PD-L1 (exoPD-L1) has recently received significant attention as a biomarker predicting immunotherapeutic responses involving the PD1/PD-L1 pathway. However, current technologies for exosomal analysis rely primarily on bulk measurements that do not consider the heterogeneity found within exosomal subpopulations. Here, we present a nanoscale cytometry platform NanoEPIC, enabling phenotypic sorting and exoPD-L1 profiling from blood plasma. We highlight the efficacy of NanoEPIC in monitoring anti-PD-1 immunotherapy through the interrogation of exoPD-L1. NanoEPIC generates signature exoPD-L1 patterns in responders and non-responders. In mice treated with PD1-targeted immunotherapy, exoPD-L1 is correlated with tumor growth, PD-L1 burden in tumors, and the immune suppression of CD8+ tumor-infiltrating lymphocytes. Small extracellular vesicles (sEVs) with different PD-L1 expression levels display distinctive inhibitory effects on CD8 + T cells. NanoEPIC offers robust, high-throughput profiling of exosomal markers, enabling sEV subpopulation analysis. This platform holds the potential for enhanced cancer screening, personalized treatment, and therapeutic response monitoring.
Original languageEnglish
Number of pages0
JournalNature Communications
Volume14
Issue number1
Early online date11 Sept 2023
DOIs
Publication statusPublished - 11 Sept 2023

Fingerprint

Dive into the research topics of 'A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles'. Together they form a unique fingerprint.

Cite this